Viracta closes Series C; new partner Salubris participates

Viracta Therapeutics Inc. closed its Series C round, led by a $10mm investment from new partner Shenzhen Salubris Pharmaceuticals Co. Ltd. Returning backers NantKwest, Latterell Venture Partners, and Forward Ventures also participated. Viracta is developing treatments for viral-related cancers, and concurrent with the Series C round, granted Salubris exclusive rights to develop and sell its lead candidate nanatinostat/valganciclovir in China for Epstein Barr virus-associated lymphomas, solid tumors, and for the prevention of EBV-associated post-transplant lymphoproliferative disorder. The project is currently in Phase Ib/II trials.